Business Context and Reporting Period
This Form 8-K Current Report was filed by Bristol-Myers Squibb Company on March 3, 2022, covering events occurring on March 1 and March 2, 2022. The filing addresses the early participation results, upsizing, and early settlement of previously announced cash tender offers to purchase notes issued by Bristol-Myers Squibb and its wholly owned subsidiary, Celgene Corporation.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, or overall liquidity. The financial focus is strictly on the debt restructuring activity regarding the tender offers. The following securities were subject to the offers:
- 1.000% Notes due 2025 (Trading Symbol: BMY25)
- 1.750% Notes due 2035 (Trading Symbol: BMY35)
- Celgene Contingent Value Rights (Trading Symbol: CELG RT)
Material Changes
The primary material change reported is the execution of the cash tender offers. Key developments include:
- Early Participation and Upsizing: The company announced early participation results and an upsizing of the offers on March 1, 2022.
- Settlement: The offers were settled early.
- Pricing Terms: Accepted amounts and pricing terms were announced on March 2, 2022.
Specific numerical details regarding the total principal amount accepted, the premium paid, or the exact pricing terms are not contained in the body of this filing but are referenced in the attached press releases (Exhibits 99.1 and 99.2).
Guidance, Outlook, and Risks
This filing does not contain updated financial guidance, forward-looking outlook statements, or a discussion of general business risks. The document serves solely to disclose the status of the debt tender offers. The filing notes that the offers are subject to the terms and conditions described in the Offer to Purchase dated February 15, 2022.
Investor Verification Checklist
- Review Exhibit 99.1 (March 1, 2022 Press Release) for specific early participation results and upsizing details.
- Review Exhibit 99.2 (March 2, 2022 Press Release) for the final accepted amounts and pricing terms of the tender offers.
- Verify the impact of the debt reduction on the company's total leverage ratio using the most recent 10-K or 10-Q filings.
- Confirm the settlement date and cash outflow associated with the early settlement of the notes.